Kruppel-like factor 2 mRNA 3'-untranslated region (KLF2 mRNA 3'-UTR) (KLF2 3'-UTR)

The Kruppel-like factor 2 (KLF2) mRNA 3'-untranslated region (3'-UTR) is a critical regulatory segment of the KLF2 transcript, which encodes a zinc-finger transcription factor essential for maintaining vascular endothelial health (Dekker et al., 2006, Blood). KLF2 is primarily expressed in endothelial cells, where it exerts anti-inflammatory, anti-thrombotic, and pro-fibrinolytic effects in response to laminar shear stress (Abderrazak et al., 2015, ATVB). The 3'-UTR of KLF2 mRNA contains multiple conserved binding sites for microRNAs, most notably miR-92a, which negatively regulates KLF2 expression by promoting mRNA degradation or inhibiting translation (Wu et al., 2011, Blood). Because KLF2 deficiency is linked to the progression of atherosclerosis and chronic inflammation, the KLF2 mRNA 3'-UTR has emerged as a strategic target for therapeutic intervention. Experimental strategies, such as the use of antagomirs like MRG-110 against miR-92a, aim to block these inhibitory interactions at the 3'-UTR to restore or enhance KLF2 protein levels and improve vascular function (Loyer et al., 2014, Circ Res). While no small-molecule drugs currently target this region directly in clinical practice, it remains a focal point for RNA-based therapies designed to treat cardiovascular and inflammatory diseases.

Other names

KLF2 3'-UTRLung Kruppel-like factor 2 mRNA 3'-untranslated regionLKLF 3'-UTR

The primary mechanism involves the use of antagomirs or antisense oligonucleotides to competitively bind to microRNA recognition elements (MREs) within the 3'-UTR, thereby preventing microRNA-induced silencing complex (miRISC) recruitment and subsequent mRNA degradation (Loyer et al., 2014, Circ Res). Indirect modulation by statins also enhances KLF2 expression, potentially by altering the microRNA profile that targets this region (Parmar et al., 2005, J Clin Invest).